SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Routine cardiovascular risk assessments and timely implementation of GLP-1RAs and SGLT2 inhibitors are also essential for reducing the adverse CVEs in patients with NAFLD and type 2 diabetes.